Cargando…

Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study

BACKGROUND: We aimed to investigate the factors influencing the cure, recurrence, and metastasis rates of stage IA lung adenocarcinoma, using a mixed cure model. METHODS: A total of 1,064 patients who underwent video-assisted thoracoscopic pulmonectomy were included. Variable screening was performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhixin, Chen, Dinghang, Hong, Zhinuan, Kang, Mingqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619226/
https://www.ncbi.nlm.nih.gov/pubmed/37907906
http://dx.doi.org/10.1186/s12890-023-02725-9
_version_ 1785129940877836288
author Huang, Zhixin
Chen, Dinghang
Hong, Zhinuan
Kang, Mingqiang
author_facet Huang, Zhixin
Chen, Dinghang
Hong, Zhinuan
Kang, Mingqiang
author_sort Huang, Zhixin
collection PubMed
description BACKGROUND: We aimed to investigate the factors influencing the cure, recurrence, and metastasis rates of stage IA lung adenocarcinoma, using a mixed cure model. METHODS: A total of 1,064 patients who underwent video-assisted thoracoscopic pulmonectomy were included. Variable screening was performed using the random forest algorithm and least absolute shrinkage and selection operator approaches. The mixed cure model was used to identify factors affecting patient cure and survival, and a sequential analysis was performed on 5%, 10%, and 20% of the presentational subtype concurrently. A receiver operating characteristics curve was used to determine the best model and construct a nomogram to predict the cure rate. RESULTS: The median follow-up time was 58 (range: 3–115) months. Results from the cure part of the mixed model indicated that the predominant subtype, presentational subtype, and tumor diameter were the main prognostic factors affecting cure rate. Therefore, the nomogram to predict the cure rate was constructed based on these factors. The survival part indicated that the predominant subtype was the only factor that influenced recurrence and metastasis. A sequential analysis of the presentational subtype showed it had no significant effect on survival (P > 0.05). Regardless of the recording mode, no significant improvement was observed in the model's discriminative ability. Only a few postoperative pathological specimens showed lymphovascular invasion (LVI); however, the survival curve suggested a significant effect on patient survival. CONCLUSIONS: After excluding the existence of long-term survivors, the predominant tumor subtype was determined to be the only factor influencing recurrence and metastasis. Although LVI is rare in stage IA lung adenocarcinoma, its significance cannot be discounted in terms of determining patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02725-9.
format Online
Article
Text
id pubmed-10619226
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106192262023-11-02 Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study Huang, Zhixin Chen, Dinghang Hong, Zhinuan Kang, Mingqiang BMC Pulm Med Research BACKGROUND: We aimed to investigate the factors influencing the cure, recurrence, and metastasis rates of stage IA lung adenocarcinoma, using a mixed cure model. METHODS: A total of 1,064 patients who underwent video-assisted thoracoscopic pulmonectomy were included. Variable screening was performed using the random forest algorithm and least absolute shrinkage and selection operator approaches. The mixed cure model was used to identify factors affecting patient cure and survival, and a sequential analysis was performed on 5%, 10%, and 20% of the presentational subtype concurrently. A receiver operating characteristics curve was used to determine the best model and construct a nomogram to predict the cure rate. RESULTS: The median follow-up time was 58 (range: 3–115) months. Results from the cure part of the mixed model indicated that the predominant subtype, presentational subtype, and tumor diameter were the main prognostic factors affecting cure rate. Therefore, the nomogram to predict the cure rate was constructed based on these factors. The survival part indicated that the predominant subtype was the only factor that influenced recurrence and metastasis. A sequential analysis of the presentational subtype showed it had no significant effect on survival (P > 0.05). Regardless of the recording mode, no significant improvement was observed in the model's discriminative ability. Only a few postoperative pathological specimens showed lymphovascular invasion (LVI); however, the survival curve suggested a significant effect on patient survival. CONCLUSIONS: After excluding the existence of long-term survivors, the predominant tumor subtype was determined to be the only factor influencing recurrence and metastasis. Although LVI is rare in stage IA lung adenocarcinoma, its significance cannot be discounted in terms of determining patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02725-9. BioMed Central 2023-10-31 /pmc/articles/PMC10619226/ /pubmed/37907906 http://dx.doi.org/10.1186/s12890-023-02725-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Zhixin
Chen, Dinghang
Hong, Zhinuan
Kang, Mingqiang
Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title_full Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title_fullStr Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title_full_unstemmed Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title_short Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
title_sort estimating the cure proportion of stage ia lung adenocarcinoma: a population-based study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619226/
https://www.ncbi.nlm.nih.gov/pubmed/37907906
http://dx.doi.org/10.1186/s12890-023-02725-9
work_keys_str_mv AT huangzhixin estimatingthecureproportionofstageialungadenocarcinomaapopulationbasedstudy
AT chendinghang estimatingthecureproportionofstageialungadenocarcinomaapopulationbasedstudy
AT hongzhinuan estimatingthecureproportionofstageialungadenocarcinomaapopulationbasedstudy
AT kangmingqiang estimatingthecureproportionofstageialungadenocarcinomaapopulationbasedstudy